$JD HEALTH(06618)$ delivered strong Q3 2025 results, with revenue up 29% and profit nearly doubling. Its share price has rebounded sharply, rising 144% this year after falling over 90% from 2020–2023. The company expanded partnerships with major pharma and medical device firms and strengthened its AI-driven Internet healthcare ecosystem. User activity and service scale continue to grow, with over 200 million active users and 500,000 daily consultation orders. Analysts believe the pharmaceutical segment will remain the key growth driver as JD Health deepens its full-cycle health management services.

$Stryker(SYK)$ Outlook FY Organic Net Sales Growth 9.8-10.2%